The US market for Hemostats and Sealants recovered in Q417, up +5.0% YoY, in line with historic growth rates. While biologic sealants continue to lag, every other segment grew, led by absorbable hemostats and fibrin sealants.
SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 Hemostats & Sealants Market Recap and Financial Dashboard.
As reported in SmartTRAK’s Financial Dashboard, almost every manufacturer competing in the Hemostats and Sealants market saw revenue growth in Q417/FY17, led by Baxter, Ethicon and Cryolife in Q417 and by Baxter and Integra for FY17 ...
Pfizer and CR Bard (now part of Becton Dickinson) were the only companies that did not post growth in 2017.
Among the topics covered in the Q417, FY17 Hemostats & Sealants Market Recap are:
- The Hemostats & Sealant Market - A Return to Growth
- Market Leaders
- Hemostats: Surgicel's Rise
- Sealants: Fibrin and Synthetics Drive Market Growth
- Key Market Developments
Read the entire Market Recap including news, data and analysis*...
*This article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
